Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Darizmetinib (HRX215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | In stock | $ 1,970.00 | |
50 mg | In stock | $ 2,580.00 | |
100 mg | In stock | $ 3,400.00 |
Description | Darizmetinib (HRX215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration. |
Synonyms | HRX215 |
Molecular Weight | 457.46 |
Formula | C21H17F2N5O3S |
CAS No. | 2369583-33-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Darizmetinib 2369583-33-3 MAPK HRX215 HRX-215 HRX 215 inhibitor inhibit